100V/20A 7in1 Tester Voltmeter Capacity Temperature Time Current Voltage OLED Other Test Meters & Detectors


  1. Home
  2. 100V/20A 7in1 Tester Voltmeter Capacity Temperature Time Current Voltage OLED
  1. facebook
  2. twitter
  3. linkedin
  4. pinterest
100V/20A 7in1 OLED Voltage Current Time Temperature Capacity Voltmeter Tester
Condition: New: A brand-new, unused, unopened, undamaged item in its original packaging (where packaging is Brand:

ELEGIANT

Time Measurement Range: 0-99h59min Type: OLED Voltage Voltmeter
Power Measurement Range: 0-999.9-2000 W MPN:

PbV564323

Temperature Measurement Range: -15 °c ~60°c Voltage Measurement Range: DC00.0-99.9V
Product Size: 48mm*29mm*22mm (L*W*H) Current Measurement Range: DC00.0-20.0A
Manufacturer Part Number:

PbV564323

UPC:

Does not apply

ISBN:

Does not apply









published on tue nov 09 2021

100V/20A 7in1 Tester Voltmeter Capacity Temperature Time Current Voltage OLED Other Test Meters & Detectors

gandhi, s., klein, j., robertson, a., pena-hernandez, m. a.,

100V/20A 7in1 Tester Voltmeter Capacity Temperature Time Current Voltage OLED Other Test Meters & Detectors

lin, m. j., roychoudhury, p., lu, p., fournier, j., ferguson, d., mohamed bakhash, s. a., muenker, m. c., srivathsan, a., wunder, e. a., kerantzas, n., wang, w., pyle, a., wilen, c. b., ogbuagu, o., greninger ,, a. l., iwasaki, a., schulz, w. l., ko, a. i.

sars-cov-2 remdesivir resistance mutations have been generated in vitro but have not been reported in patients receiving treatment with the antiviral agent. we present a case of an immunocompromised patient with acquired b-cell deficiency who developed an indolent, protracted course of sars-cov-2 infection. remdesivir therapy alleviated symptoms and produced a transient virologic response, but her course was complicated by recrudescence of high-grade viral shedding. whole genome sequencing identified a mutation, e802d, in the nsp12 rna-dependent rna polymerase which was not present in pre-treatment specimens. in vitro experiments demonstrated that the mutation conferred a ~6-fold increase in remdesivir ic50 but resulted in a fitness cost in the absence of remdesivir. sustained clinical and virologic response was achieved after treatment with casirivimab-imdevimab. although the fitness cost observed in vitro may limit the risk posed by e802d,

, this case illustrates the importance of monitoring for remdesivir resistance and the potential benefit of combinatorial therapies in immunocompromised patients with sars-cov-2 infection.

509
1.2k
EVGENIA.RU RSS